Effect of dexamethasone administered with magnesium sulfate on inflammation-mediated degradation of the blood-brain barrier using an in vitro model

Reproductive Sciences

Volumn 21, Issue 4, 2014, Pages 483-491

  Lutgendorf, Monica A ^a   Ippolito, Danielle L ^a   Mesngon, Mariano T ^a   Tinnemore, Deborah ^a   Dehart, Mary Jo ^a   Dolinsky, Brad M ^a   Napolitano, Peter G ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

magnesium; matrix metalloproteinase 9; neuroprotection

Indexed keywords

AUTACOID; CONDITIONED MEDIUM; DEXAMETHASONE; GELATINASE B; GLUCOCORTICOID; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; PROTEIN ZO1; TJP1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANIMAL; ASTROCYTE; BLOOD BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE; CONDITIONED MEDIUM; DRUG EFFECTS; ENCEPHALITIS; ENDOTHELIUM CELL; HUMAN; IMMUNOLOGY; IMPEDANCE; METABOLISM; PATHOLOGY; RAT;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CELL LINE; CULTURE MEDIA, CONDITIONED; DEXAMETHASONE; ELECTRIC IMPEDANCE; ENCEPHALITIS; ENDOTHELIAL CELLS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION MEDIATORS; MAGNESIUM SULFATE; MATRIX METALLOPROTEINASE 9; NEUROPROTECTIVE AGENTS; RATS; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84898998055     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719113503410     Document Type: Article

References (58)

1. Volpe JJ. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009 ; 8 (1). 110-124
2. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 2009 ; 200 (6). 595-609
3. Murata Y, Itakura A, Matsuzawa K, Okumura A, Wakai K, Mizutani S. Possible antenatal and perinatal related factors in development of cystic periventricular leukomalacia. Brain Dev. 2005 ; 27 (1). 17-21 (Pubitemid 40051299)
4. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA. 2000 ; 284 (11). 1417-1424
5. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. Am J Obstet Gynecol. 1998 ; 179 (1). 194-202 (Pubitemid 28394495)
6. Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. 1997 ; 177 (1). 19-26 (Pubitemid 27327305)
7. Yoon BH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol. 2000 ; 182 (3). 675-681 (Pubitemid 30207333)
8. Yoon BH, Park CW, Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG. 2003 ; 110 (suppl 20). 124-127 (Pubitemid 36577401)
9. Yoon BH, Romero R, Yang SH, et al. Interleukin-6 concentrations in umbilical cord plasma are elevated in neonates with white matter lesions associated with periventricular leukomalacia. Am J Obstet Gynecol. 1996 ; 174 (5). 1433-1440 (Pubitemid 26165257)
10. Deguchi K, Mizuguchi M, Takashima S. Immunohistochemical expression of tumor necrosis factor alpha in neonatal leukomalacia. Pediatr Neurol. 1996 ; 14 (1). 13-16 (Pubitemid 26069526)
11. Kadhim H, Tabarki B, De Prez C, Sebire G. Cytokine immunoreactivity in cortical and subcortical neurons in periventricular leukomalacia: are cytokines implicated in neuronal dysfunction in cerebral palsy?. Acta Neuropathol. 2003 ; 105 (3). 209-216 (Pubitemid 36798811)
12. Yoon BH, Romero R, Kim CJ, et al. High expression of tumor necrosis factor-alpha and interleukin-6 in periventricular leukomalacia. Am J Obstet Gynecol. 1997 ; 177 (2). 406-411 (Pubitemid 27385721)
13. McAdams RM, Juul SE. The role of cytokines and inflammatory cells in perinatal brain injury. Neurol Res Int. 2012; ; 2012: 561494
14. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist. 2010 ; 16 (2). 156-170
15. Romero R, Chaiworapongsa T, Espinoza J, et al. Fetal plasma MMP-9 concentrations are elevated in preterm premature rupture of the membranes. Am J Obstet Gynecol. 2002 ; 187 (5). 1125-1130 (Pubitemid 35397444)
16. Vadillo-Ortega F, Hernandez A, Gonzalez-Avila G, Bermejo L, Iwata K, Strauss JF. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes. Am J Obstet Gynecol. 1996 ; 174 (4). 1371-1376 (Pubitemid 26131163)
17. Weiss A, Goldman S, Shalev E. The matrix metalloproteinases (MMPS) in the decidua and fetal membranes. Front Biosci. 2007 ; 12: 649-659 (Pubitemid 46860207)
18. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA. 1995 ; 273 (5). 413-418
19. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999 ; 341 (16). 1190-1196 (Pubitemid 29480657)
20. Kent A, Lomas F, Hurrion E, Dahlstrom JE. Antenatal steroids may reduce adverse neurological outcome following chorioamnionitis: neurodevelopmental outcome and chorioamnionitis in premature infants. J Paediatr Child Health. 2005 ; 41 (4). 186-190 (Pubitemid 40646628)
21. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010 ; 115 (3). 669-671
22. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009 ; (1). CD004661
23. Sugimoto J, Romani AM, Valentin-Torres AM, et al. Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol. 2012 ; 188 (12). 6338-6346
24. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003 ; 290 (20). 2669-2676 (Pubitemid 37475594)
25. Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. BJOG. 2007 ; 114 (3). 310-318
26. Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008 ; 359 (9). 895-905
27. Berger I, Peleg O, Ofek-Shlomai N. Inflammation and early brain injury in term and preterm infants. Isr Med Assoc J. 2012 ; 14 (5). 318-323
28. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res. 1997 ; 42 (1). 1-8 (Pubitemid 27276750)
29. Baud O, Emilie D, Pelletier E, et al. Amniotic fluid concentrations of interleukin-1beta, interleukin-6 and TNF-alpha in chorioamnionitis before 32 weeks of gestation: histological associations and neonatal outcome. Br J Obstet Gynaecol. 1999 ; 106 (1). 72-77 (Pubitemid 29041979)
30. Procianoy RS, Silveira RC. Association between high cytokine levels with white matter injury in preterm infants with sepsis. Pediatr Crit Care Med. 2012 ; 13 (2). 183-187
31. Dollner H, Vatten L, Halgunset J, Rahimipoor S, Austgulen R. Histologic chorioamnionitis and umbilical serum levels of pro-inflammatory cytokines and cytokine inhibitors. BJOG. 2002 ; 109 (5). 534-539 (Pubitemid 37337994)
32. Shalak LF, Laptook AR, Jafri HS, Ramilo O, Perlman JM. Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. Pediatrics. 2002 ; 110 (4). 673-680
33. Deli MA, Abraham CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol. 2005 ; 25 (1). 59-127 (Pubitemid 40558585)
34. Kacimi R, Giffard RG, Yenari MA. Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J Inflamm (Lond). 2011 ; 8: 7
35. Hurst RD, Fritz IB. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J Cell Physiol. 1996 ; 167 (1). 81-88 (Pubitemid 26108736)
36. Rochelson B, Dowling O, Schwartz N, Metz CN. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFkappaB pathway. J Reprod Immunol. 2007 ; 73 (2). 101-107 (Pubitemid 46399949)
37. Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD. A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport. 2001 ; 12 (7). 1329-1334 (Pubitemid 32476123)
38. Cecchelli R, Dehouck B, Descamps L, et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev. 1999 ; 36 (2-3). 165-178 (Pubitemid 29121970)
39. Burke-Gaffney A, Keenan AK. Modulation of human endothelial cell permeability by combinations of the cytokines interleukin-1 alpha/beta, tumor necrosis factor-alpha and interferon-gamma. Immunopharmacology. 1993 ; 25 (1). 1-9 (Pubitemid 23114247)
40. Forster C, Kahles T, Kietz S, Drenckhahn D. Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol. 2007 ; 580 (pt 3). 937-949 (Pubitemid 46915250)
41. Kream J, Mulay S, Fukushima DK, Solomon S. Determination of plasma dexamethasone in the mother and the newborn after administration of the hormone in a clinical trial. J Clin Endocrinol Metab. 1983 ; 56 (1). 127-133 (Pubitemid 13212318)
42. Rouse DJ. Magnesium sulfate (MgSO4) dose and timing, and umbilical cord Mg++ concentration: relationship to cerebral palsy (CP). Am J Obstet Gynecol. 2008 ; 199(6): S46
43. Johnson LH, Mapp DC, Rouse DJ, et al. Association of cord blood magnesium concentration and neonatal resuscitation. J Pediatr. 2012 ; 160 (4). 573-577
44. Liu KC, Jacobs DT, Dunn BD, Fanning AS, Cheney RE. Myosin-X functions in polarized epithelial cells. Mol Biol Cell. 2012 ; 23 (9). 1675-1687
45. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012 ; 9 (7). 671-675
46. Arganda-Carreras I, Fernandez-Gonzalez R, Munoz-Barrutia A. Ortiz-De-Solorzano C. 3D reconstruction of histological sections: application to mammary gland tissue. Microsc Res Tech. 2010 ; 73 (11). 1019-1029
47. Napolitano PG. The effect of magnesium sulfate on the activity of matrix metalloproteinase-9 in fetal cord plasma and human umbilical vein endothelial cells. Am J Obstet Gynecol. 2010 ; 203 (4). e371-375
48. Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet Gynecol. 2009 ; 114 (3). 669-673
49. Agarwal R, Chiswick ML, Rimmer S, et al. Antenatal steroids are associated with a reduction in the incidence of cerebral white matter lesions in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 2002 ; 86 (2). F96 - F101
50. Kaur C, Ling EA. Periventricular white matter damage in the hypoxic neonatal brain: role of microglial cells. Prog Neurobiol. 2009 ; 87 (4). 264-280
51. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery. 2009 ; 65 (4). 702-708
52. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004 ; 84 (3). 869-901 (Pubitemid 38823769)
53. Grabb PA, Gilbert MR. Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg. 1995 ; 82 (6). 1053-1058
54. Dittmar MS, Petermichl W, Schlachetzki F, Graf BM, Gruber M. Isoflurane induces endothelial apoptosis of the post-hypoxic blood-brain barrier in a transdifferentiated human umbilical vein endothelial cell model. PLoS One. 2012 ; 7 (6). e38260
55. Raub TJ, Kuentzel SL, Sawada GA. Permeability of bovine brain microvessel endothelial cells in vitro: barrier tightening by a factor released from astroglioma cells. Exp Cell Res. 1992 ; 199 (2). 330-340
56. Brown J, Reading SJ, Jones S, et al. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest. 2000 ; 80 (1). 37-45 (Pubitemid 30067378)
57. Kiessling F, Kartenbeck J, Haller C. Cell-cell contacts in the human cell line ECV304 exhibit both endothelial and epithelial characteristics. Cell Tissue Res. 1999 ; 297 (1). 131-140 (Pubitemid 29313284)
58. Suda K, Rothen-Rutishauser B, Gunthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev Biol Anim. 2001 ; 37 (8). 505-514 (Pubitemid 32973239)